PMCB
PharmaCyte Biotech, Inc.
There isn't enough reported data to score PMCB yet.
PMCB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
PMCB's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
PMCB PE Valuation
PMCB has no meaningful PE right now: it lost money over the past year.
PMCB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect PMCB's earnings, revenue and profitability to hold roughly steady.
PMCB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.48 | -4233% |
| Q2 2026 | -$3.17 | -199% |
| Q1 2021 | $0.00 | $0.00 |
| Q4 2020 | $0.00 | $0.00 |
PMCB has swung to a loss: it lost $2.48 per share over the past year, after a profit the year before.
PMCB Quarterly Revenue
PMCB's revenue is shrinking: $0 last quarter.
PMCB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$780.9K | +$1.2M |
| Q2 2026 | -$1.4M | -$352.2K |
| Q1 2026 | -$786.8K | -$277K |
| Q4 2025 | -$979.5K | +$75.2K |
| Q3 2025 | -$2M | -$1.6M |
| Q2 2025 | -$1M | -$707.4K |
| Q1 2025 | -$509.9K | -$332.8K |
| Q4 2024 | -$1.1M | +$929.6K |
PMCB has burned cash in almost every quarter: −$4M over the past year, against −$5M the year before.
PMCB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +1.5M shares |
| 1 year | +46% | +3.4M shares |
| 3 years | -43% | -8.3M shares |
| 5 years | +621% | +9.2M shares |
PMCB has 11M diluted shares, up 46% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | $401,625 |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $171,543 |
| Q1 2025 | $225,025 |
| Q4 2024 | $1.4M |
| Q3 2024 | $742,179 |
PMCB Net Leverage
PMCB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
PMCB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.0 | Neutral |
| Stochastic | 20.9 | Neutral |
PMCB's weekly RSI is 38 (neutral) and its Stochastic is 21 (neutral).
PMCB PE vs Healthcare Sector
| Metric | PMCB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
PMCB has no meaningful PE right now: it lost money over the past year.
PMCB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.38 | 5.3% above |
| 20 week MA | $0.49 | 18% below |
| 50 week MA | $0.66 | 39% below |
| 100 week MA | $0.93 | 57% below |
| 200 week MA | $1.62 | 75% below |
PMCB has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 75% below its 200-week average.
PMCB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $61.2 | $8.37 | -86% |
| 2021 | $8.37 | $2.69 | -68% |
| 2022 | $2.69 | $2.92 | +8.6% |
| 2023 | $2.92 | $2.16 | -26% |
| 2024 | $2.16 | $1.57 | -27% |
| 2025 | $1.57 | $0.71 | -55% |
| 2026 YTD | $0.71 | $0.40 | -44% |
PMCB has finished three years in a row lower, and it's down 44% so far in 2026.